Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VTGN 
VistaGen Therapeutics Inc (VTGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: VTGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -64.26% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 75.36M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 143159 | Beta 0.62 | 52 Weeks Range 2.22 - 5.74 | Updated Date 04/1/2025 |
52 Weeks Range 2.22 - 5.74 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.48 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6461.54% |
Management Effectiveness
Return on Assets (TTM) -29.57% | Return on Equity (TTM) -46.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -15269030 | Price to Sales(TTM) 107.96 |
Enterprise Value -15269030 | Price to Sales(TTM) 107.96 | ||
Enterprise Value to Revenue 8.05 | Enterprise Value to EBITDA -0.19 | Shares Outstanding 28862100 | Shares Floating 20224817 |
Shares Outstanding 28862100 | Shares Floating 20224817 | ||
Percent Insiders 0.26 | Percent Institutions 52.64 |
Analyst Ratings
Rating 4.75 | Target Price 13 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
VistaGen Therapeutics Inc
Company Overview
History and Background
VistaGen Therapeutics Inc. was founded in 2005. It is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for anxiety, depression, and other central nervous system (CNS) disorders.
Core Business Areas
- CNS Disorders: Focuses on developing novel therapies for anxiety, depression, and other CNS disorders. Core product is Fasedienol, a nasal spray for social anxiety disorder (SAD).
Leadership and Structure
Shawn K. Singh is the Chief Executive Officer. The company has a standard organizational structure with departments focusing on research, development, clinical trials, and corporate operations.
Top Products and Market Share
Key Offerings
- Fasedienol (PH94B): A rapid-onset nasal spray being developed for the acute treatment of social anxiety disorder (SAD). Phase 3 trials are underway. Market share is currently 0% as it's pre-commercial. Competitors will be existing SAD treatments like SSRIs and benzodiazepines.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the CNS therapeutics market, is large and growing, driven by increasing prevalence of mental health disorders and demand for novel treatments.
Positioning
VistaGen is positioned as a company developing innovative, rapid-onset therapies for CNS disorders. Their focus on pherine-based drugs sets them apart from companies relying on traditional neurotransmitter-based approaches.
Total Addressable Market (TAM)
The total addressable market for anxiety disorders is estimated to be billions of dollars annually. VistaGen aims to capture a significant portion of this market with their novel therapies. Market size for SAD alone is estimated to be in billions of dollars.
Upturn SWOT Analysis
Strengths
- Novel technology platform (pheromone-based drugs)
- Focus on underserved mental health markets
- Experienced management team
- Potential for rapid-onset therapies
Weaknesses
- Single lead product (Fasedienol)
- High dependence on clinical trial success
- Limited commercialization experience
- Significant cash burn
Opportunities
- Successful commercialization of Fasedienol
- Expansion of pipeline into other CNS disorders
- Partnerships with larger pharmaceutical companies
- Growing awareness and acceptance of mental health treatments
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging therapies
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- LLY
- PFE
- VRX
Competitive Landscape
VistaGen's advantage lies in its novel pherine-based approach. Disadvantage is competing with established players in the CNS market.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been driven by advancement of pipeline programs through clinical development. The company has not yet achieved commercial revenue.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals for Fasedienol and other pipeline candidates. Analyst estimates vary widely due to the inherent uncertainty in drug development.
Recent Initiatives: Focus on advancing Phase 3 clinical trials for Fasedienol in SAD. Exploring potential partnerships for commercialization.
Summary
VistaGen is a high-risk, high-reward biopharmaceutical company focused on innovative CNS therapies. Its success hinges on positive clinical trial outcomes for Fasedienol and other pipeline candidates. The company needs to carefully manage its cash burn and explore potential partnerships to support commercialization. While the company's focus on novel approaches presents opportunity, it faces intense competition from established players.
Similar Companies
- AVXL
- SAGE
- AXSM
Sources and Disclaimers
Data Sources:
- Company website, SEC filings, Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be subject to change. Past performance is not indicative of future results. Please perform thorough due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About VistaGen Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2016-05-06 | President, CEO & Director Mr. Shawn K. Singh J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 48 | Website https://www.vistagen.com |
Full time employees 48 | Website https://www.vistagen.com | ||
Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company's product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women's health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.